Sionna Therapeutics (SION)
Develops NBD1-stabilizing and complementary CFTR modulators for cystic fibrosis.
$5.59
vs last close−0.43 (−7.23%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
estimated · in 42 days
EPS estimate
−$0.64
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$3.38−$0.62−$0.41−$0.46−$0.46−$0.60−$0.66Pending
Estimate−$1.28−$0.45−$0.68−$0.52−$0.54−$0.52−$0.65−$0.64
Surprise−164.8%−37.8%+39.7%+11.5%+14.7%−15.4%−1.5%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.54 | — | — |
| Sep 2027 | −$0.52 | — | — |
| Jun 2027 | −$0.50 | — | — |
| Mar 2027 | −$0.51 | — | — |
| Dec 2026 | −$0.56 | — | — |
| Nov 2026 | −$0.64 | — | — |
| Aug 2026 | −$0.65 | −$0.66 | −1.5% |
| May 2026 | −$0.52 | −$0.60 | −15.4% |
| Mar 2026 | −$0.54 | −$0.46 | +14.7% |
| Nov 2025 | −$0.52 | −$0.46 | +11.5% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Jan 2025 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.54 | — | — | $0 | — | — | — |
| Sep 2027 | −$0.52 | — | — | $0 | — | — | — |
| Jun 2027 | −$0.50 | — | — | $0 | — | — | — |
| Mar 2027 | −$0.51 | — | — | $0 | — | — | — |
| Dec 2026 | −$0.56 | — | — | $0 | — | — | — |
| Nov 4, 2026 | −$0.64 | — | — | $0 | — | — | — |
| Aug 6, 2026 | −$0.65 | −$0.66 | −1.5% | — | — | — | +4.8% |
| May 12, 2026 | −$0.52 | −$0.60 | −15.4% | — | — | — | −10.9% |
| Mar 2, 2026 | −$0.54 | −$0.46 | +14.7% | — | — | — | −7.2% |
| Nov 5, 2025 | −$0.52 | −$0.46 | +11.5% | — | — | — | −1.6% |
| Aug 11, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 20, 2025 | |||||||
| Jan 17, 2025 |